Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.
A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.
ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.